Figure 1. Inclusion and exclusion of subjects. ^aAdults (≥18–≤60 y); ^belderly (≥61 y); ^cimmunogenicity was analyzed as per protocol using HI and SRH assays according to CHMP criteria; ^dsafety assessment was conducted by collection of any solicited local and systemic reactions and collection of adverse events (adverse events were defined as solicited reactions persisting after day 4 or other than solicited local and systemic reactions reported during the study period); ^eone subject was not available for visit 3 and was therefore excluded from immunogenicity analysis